Table 3.

Efficient screening strategies among Transplant Cystic Fibrosis patients according to screening tests used.

	Outcomes per 1,000 transplant cystic fibrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant at age 30, 3% discounted)
	Screening test		Surveillance COLs	Total COLs	Compli -cations	CRC Casesc	CRC deatha,c	LY with CRC	LYGb	Total costs (*$1,000)	Net costs (*$1,000)	Reductionsb CRC incidencec	(%) CRC mortalityc	ICER (*$1,000)
	FIT	COLs
Colonoscopy strategies (main analysis)
No screening	0	0	0	30	0	52	22	115	0	2,065	0	0	0	-
COL 45–55 y, 10 y	0	199	342	553	2	39	9	139	28	2,438	374	25	57	1
COL 45–55 y, 5 y	0	200	343	554	2	39	9	139	28	2,439	374	25	58	7
COL 40–55 y, 5 y	0	324	591	923	3	34	7	129	42	2,601	536	36	70	12
COL 35–55 y, 5 y	0	607	838	1,451	3	31	5	122	52	3,028	963	41	77	45
COL 35–55 y, 3 y	0	642	1,265	1,912	4	26	4	110	56	3,347	1,282	49	82	71
COL 30–55 y, 3 y	0	1,511	1,826	3,340	5	25	3	99	64	4,622	2,558	53	87	166
All screening strategies (supplementary analysis)
No screening	0	0	0	30	0	52	22	115	0	2,065	0	0	0	-
COL 45–55 y, 10 y	0	199	342	553	2	39	9	139	28	2,438	374	25	57	1
COL 45–55 y, 5 y	0	200	343	554	2	39	9	139	28	2,439	374	25	58	7
COL 40–55 y, 5 y	0	324	591	923	3	34	7	129	42	2,601	536	36	70	12
FIT 35–55 y	3,419	0	377	620	2	42	6	175	48	2,756	691	19	72	27
FIT 30–55 y	6,702	0	460	811	2	41	5	177	54	3,050	985	21	76	47
FIT 30–60 y	6,722	0	463	816	2	41	5	178	54	3,068	1,003	20	77	86
COL 35–55 y, 3 y	0	642	1,265	1,912	4	26	4	110	56	3,347	1,282	49	82	156
COL 30–55 y, 3 y	0	1,511	1,826	3,340	5	25	3	99	64	4,622	2,558	53	87	166

COL indicates colonoscopy; CRC, colorectal cancer; FIT = Fecal Immunochemical Test; LY, Life-years; LYG, LY gained compared with no screening; ICER, Incremental cost-effectiveness ratio (Costs/LYs gained).

^aIncluding deaths from complications of screening;

^bcompared with no screening;

^cCRC cases and CRC death were not discounted.

Bold rows indicate optimal screening strategies.